Literature DB >> 25030053

The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.

Susan L Baldwin1, Valerie Reese1, Brian Granger1, Mark T Orr1, Gregory C Ireton1, Rhea N Coler1, Steven G Reed2.   

Abstract

The tuberculin skin test (TST) is a simple and inexpensive test to determine whether individuals have been exposed to Mycobacterium tuberculosis. This test is not always reliable, however, in people previously immunized with BCG and/or who have been exposed to environmental mycobacterial species due to a reaction to purified protein derivative (PPD) used in the skin test. An issue with BCG, therefore, is that the resulting sensitization to PPD in some individuals compromises the diagnostic use of the skin test. The ability to induce protective immune responses without sensitizing to the tuberculin skin test will be important properties of next-generation tuberculosis (TB) vaccine candidates. We show here that guinea pigs immunized with the candidate TB vaccine ID93/GLA-SE, currently in clinical trials, do not react to intradermal PPD administration. In contrast, positive DTH responses to both ID93 and components thereof were induced in ID93/GLA-SE-immunized animals, indicating robust but specific cellular responses were present in the immunized animals. Noninterference with the TST is an important factor for consideration in the development of a vaccine against M. tuberculosis.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25030053      PMCID: PMC4178580          DOI: 10.1128/CVI.00372-14

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  19 in total

Review 1.  New vaccines for tuberculosis.

Authors:  Stefan H E Kaufmann; Gregory Hussey; Paul-Henri Lambert
Journal:  Lancet       Date:  2010-05-18       Impact factor: 79.321

2.  MTSA-10, the product of the Rv3874 gene of Mycobacterium tuberculosis, elicits tuberculosis-specific, delayed-type hypersensitivity in guinea pigs.

Authors:  R Colangeli; J S Spencer; P Bifani; A Williams; K Lyashchenko; M A Keen; P J Hill; J Belisle; M L Gennaro
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Shaobin Shang; Crystal A Shanley; Megan L Caraway; Eileen A Orme; Marcela Henao-Tamayo; Laurel Hascall-Dove; David Ackart; Ian M Orme; Diane J Ordway; Randall J Basaraba
Journal:  Vaccine       Date:  2012-01-11       Impact factor: 3.641

4.  Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of Mycobacterium tuberculosis infection.

Authors:  Hongliang Yang; JoLynn Troudt; Ajay Grover; Kimberly Arnett; Megan Lucas; Yun Sang Cho; Helle Bielefeldt-Ohmann; Jennifer Taylor; Angelo Izzo; Karen M Dobos
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

5.  Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.

Authors:  Ann Williams; Graham J Hatch; Simon O Clark; Karen E Gooch; Kim A Hatch; Graham A Hall; Kris Huygen; Tom H M Ottenhoff; Kees L M C Franken; Peter Andersen; T Mark Doherty; Stefan H E Kaufmann; Leander Grode; Peter Seiler; Carlos Martin; Brigitte Gicquel; Stewart T Cole; Priscille Brodin; Alexander S Pym; Wilfried Dalemans; Joe Cohen; Yves Lobet; Nilu Goonetilleke; Helen McShane; Adrian Hill; Tanya Parish; Debbie Smith; Neil G Stoker; Douglas B Lowrie; Gunilla Källenius; Stefan Svenson; Andrzej Pawlowski; Karen Blake; Philip D Marsh
Journal:  Tuberculosis (Edinb)       Date:  2005-01-20       Impact factor: 3.131

6.  A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Authors:  Sylvie Bertholet; Gregory C Ireton; Diane J Ordway; Hillarie Plessner Windish; Samuel O Pine; Maria Kahn; Tony Phan; Ian M Orme; Thomas S Vedvick; Susan L Baldwin; Rhea N Coler; Steven G Reed
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

7.  Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs.

Authors:  Philip J Hogarth; Keith J Jahans; Rolf Hecker; R Glyn Hewinson; Mark A Chambers
Journal:  Vaccine       Date:  2003-02-14       Impact factor: 3.641

8.  The BCG World Atlas: a database of global BCG vaccination policies and practices.

Authors:  Alice Zwerling; Marcel A Behr; Aman Verma; Timothy F Brewer; Dick Menzies; Madhukar Pai
Journal:  PLoS Med       Date:  2011-03-22       Impact factor: 11.069

9.  Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence.

Authors:  A Trajman; R E Steffen; D Menzies
Journal:  Pulm Med       Date:  2013-02-07

10.  Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use - United States, 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-10-18       Impact factor: 17.586

View more
  9 in total

Review 1.  The current status, challenges, and future developments of new tuberculosis vaccines.

Authors:  Wenping Gong; Yan Liang; Xueqiong Wu
Journal:  Hum Vaccin Immunother       Date:  2018-05-14       Impact factor: 3.452

Review 2.  A review of the BCG vaccine and other approaches toward tuberculosis eradication.

Authors:  Thomas Cho; Christopher Khatchadourian; Huy Nguyen; Yash Dara; Shuna Jung; Vishwanath Venketaraman
Journal:  Hum Vaccin Immunother       Date:  2021-03-26       Impact factor: 3.452

Review 3.  Mucosal Vaccine Development Based on Liposome Technology.

Authors:  Valentina Bernasconi; Karin Norling; Marta Bally; Fredrik Höök; Nils Y Lycke
Journal:  J Immunol Res       Date:  2016-12-29       Impact factor: 4.818

Review 4.  Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins.

Authors:  Abu Salim Mustafa
Journal:  Vaccines (Basel)       Date:  2021-01-07

5.  Systematic Evaluation of Mycobacterium tuberculosis Proteins for Antigenic Properties Identifies Rv1485 and Rv1705c as Potential Protective Subunit Vaccine Candidates.

Authors:  Yaguo Wang; Zihui Li; Shucai Wu; Joy Fleming; Chuanyou Li; Guofeng Zhu; Bo Chen; Baiguang Ren; Xingyun Wang; Boping Du; Pingjun Li; Peilei Hu; Juwang Yang; Yi Liu; Chongchen Zhou; Xian-En Zhang; Lijun Bi; Hongtai Zhang; Junmei Yang; Zongde Zhang
Journal:  Infect Immun       Date:  2021-02-16       Impact factor: 3.441

Review 6.  It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity.

Authors:  Sasha E Larsen; Brittany D Williams; Maham Rais; Rhea N Coler; Susan L Baldwin
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

7.  A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates.

Authors:  Stéphane Leung-Theung-Long; Marie Gouanvic; Charles-Antoine Coupet; Aurélie Ray; Emmanuel Tupin; Nathalie Silvestre; Jean-Baptiste Marchand; Doris Schmitt; Chantal Hoffmann; Murielle Klein; Philip Seegren; Maria C Huaman; Anthony D Cristillo; Geneviève Inchauspé
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

8.  Differential Immunogenicity and Protective Efficacy Elicited by MTO- and DMT-Adjuvanted CMFO Subunit Vaccines against Mycobacterium tuberculosis Infection.

Authors:  Nadeem Ullah; Ling Hao; Yaqi Wu; Yandi Zhang; Qing Lei; Jo-Lewis Banga Ndzouboukou; Xiaosong Lin; Xionglin Fan
Journal:  J Immunol Res       Date:  2020-09-04       Impact factor: 4.818

Review 9.  Tuberculosis vaccine development: from classic to clinical candidates.

Authors:  Junli Li; Aihua Zhao; Jun Tang; Guozhi Wang; Yanan Shi; Lingjun Zhan; Chuan Qin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-02-15       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.